Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 11

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 11
---
 not view ourselves in competition with those companies currently growing and/or selling cannabis for medicinal
or recreational “adult use” since we are primarily a research company at this stage. However, in the future WEED looks provide
both pharmaceutical grade medicinal products along with non-pharmaceutical products, such as Acapulco Gold suntan lotion as an example.
We are aware of companies that supply synthetic cannabinoids and cannabis extracts to researchers for pre-clinical and clinical investigation.
We are also aware of various companies that cultivate cannabis plants with a view to supplying herbal cannabis or non-pharmaceutical cannabis-based
formulations to patients. These activities have not been approved by the FDA or the TGA in Australia.

We have never endorsed or
supported the idea of distributing or legalizing crude herbal cannabis, or preparations derived from crude herbal cannabis for medical
use and do not believe our research to hopefully create prescription cannabinoids are the same, and therefore competitive, with crude
herbal cannabis. We believe that only a cannabinoid medication, one that is standardized in composition, formulation and dose, administered
by means of an appropriate delivery system, and tested in properly controlled pre-clinical and clinical studies, can meet the standards
of regulatory authorities around the world, including those of the FDA. We believe that any cannabinoid medication must be subjected to,
and satisfy, such rigorous scrutiny through proper accredited education and federal regulations.

As cannabis has moved through
the legalization process in North America, research groups in Canada and the Unites States, along with Israel, Australia, have initiated
work on understanding the Cannabis genome.

The methods of competition
for companies in the cannabis research market segment revolve around a variety of factors, including, but not limited to, experience of
the company’s research team, the facilities used by the company to conduct research, the instrumentation used to sequence DNA, the
company’s internal research protocols, and the company’s relationship with those in the scientific community.

9

Applying those competitive
factors to WEED, Inc.: our research team has decades of experience (including peer-reviewed publications and conference presentations),
we have dedicated over 14,000 square feet of research space to the resolution of cannabis genomics and the development of new strains,
our instrumentation is designed to sequence large pieces of DNA (>25,000 bp - 10 times larger than our typical competitors), and we
use custom bioinformatics (DNA sequence analysis software) not available to any other competitor in the industry. We believe these factors,
along with our strong relationships